eculizumab
Selected indexed studies
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (N Engl J Med, 2021) [PMID:33730455]
- Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review. (Pediatr Nephrol, 2024) [PMID:38057431]
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (N Engl J Med, 2006) [PMID:16990386]
_Worker-drafted node — pending editorial review._
Connections
eculizumab is a side effect of
Sources
- High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. (2017) pubmed
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (2021) pubmed
- Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review. (2024) pubmed
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (2006) pubmed
- A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. (2020) pubmed
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. (2019) pubmed
- Eculizumab in pregnancy: a narrative overview. (2019) pubmed
- The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms. (2024) pubmed
- Eculizumab treatment for myasthenia gravis subgroups: 2021 update. (2022) pubmed
- Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial. (2023) pubmed